Compare Ally Financial Inc (ALLY) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ally Financial Inc vs Crispr Therapeutics AG — how do they compare? Ally Financial Inc trades at $44.15 (market cap $13.32B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.17B). The key difference: Ally Financial Inc is far larger — about 2.6× Crispr Therapeutics AG's market cap, and Ally Financial Inc pays a 2.74% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| ALLY | CRSP | |
|---|---|---|
Market Cap | $13.32B | $5.17B |
Sector | Financials | Health |
52-Week High | $47.25 | $76.78 |
52-Week Low | $35.96 | $44.34 |
Dividend Yield | 2.74% | — |
Enterprise Value | — | $3.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ally Financial Inc
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
